Clinical Trials
409
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (352 trials with phase data)• Click on a phase to view related trials
SGLT2i, Pioglitazone, and Ketone Production in T1D
- Conditions
- Type1diabetes
- Interventions
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Target Recruit Count
- 24
- Registration Number
- NCT07056699
- Locations
- 🇺🇸
Texas Diabetes Institute, San Antonio, Texas, United States
The Effect Of Enamel Matrix Protein On Gingival Tissue Thickness. A Randomized Controlled Trial
- Conditions
- Dental ImplantationMissing TeethPeriodontitis, AdultMucositis
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Target Recruit Count
- 32
- Registration Number
- NCT07053969
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Microsurgery and Periodontal Healing
- Conditions
- Periodontal Diseases
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Target Recruit Count
- 25
- Registration Number
- NCT07054008
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-11
- Target Recruit Count
- 29
- Registration Number
- NCT07053306
- Locations
- 🇺🇸
Texas Diabetes Institute/UH, San Antonio, Texas, United States
SGLT2i, Pioglitazone, and Ketone Production in T2D
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Empagliflozin 25 MG plus Pioglitazone placeboDrug: Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin PlaceboDrug: Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)Drug: Pioglitazone placebo + Empagliflozin placebo
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Target Recruit Count
- 64
- Registration Number
- NCT07053319
- Locations
- 🇺🇸
Texas Diabetes Institute/UH, San Antonio, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 82
- Next
News
Breakthrough at UT Health San Antonio: Chemical Endocytic Strategy Could Transform IV Drugs into Oral Treatments
• Researchers at UT Health San Antonio have developed "chemical endocytic medicinal chemistry," a novel approach that could enable large-molecule drugs to be taken orally rather than intravenously. • The discovery leverages CD36 protein receptors on cell surfaces to facilitate cellular uptake of large and water-soluble drugs, potentially overcoming the blood-brain barrier for treating conditions like brain cancer and Alzheimer's disease. • This paradigm shift in drug delivery could revolutionize pharmaceutical development, resurrect previously abandoned drug candidates, and enable more personalized medicine based on patients' varying CD36 expression levels.
Novel Radiotherapeutic Rhenium Obisbemeda Doubles Survival Time in Glioblastoma Patients
A Phase 1 trial led by UT Health San Antonio demonstrated that Rhenium Obisbemeda more than doubled median survival time to 17 months in recurrent glioblastoma patients receiving high doses, compared to the typical 8-month survival.
Novel Senolytic Drug Shows Promise for MASLD and Liver Cancer Treatment
Researchers from UT Health San Antonio and Tulane University have developed a new drug candidate that effectively eliminates senescent "zombie cells" from the liver, showing potential for treating MASLD and liver cancer.
PharmAla to Develop Novel MDMA Dosage Form for Military PTSD Trial at UT Health San Antonio
PharmAla Biotech will supply both 40mg and new 20mg LaNeo MDMA capsules for a Department of Defense-funded PTSD treatment trial targeting active-duty military personnel.
Smartphone App Augments Medication to Reduce Opioid Use, Improve Retention
A recent study reveals that a smartphone app, when used with medication for opioid use disorder (MOUD), significantly reduces opioid use among patients.
PSMD Neuroimaging Marker Shows Promise in Identifying Dementia Risk
A new neuroimaging marker, peak-width of skeletonized mean diffusivity (PSMD), correlates with general cognition and may identify individuals at risk of dementia.
UT Health San Antonio Investigates Gut-Organ Miscommunication in Obesity and Diabetes
Dr. Marzieh Salehi challenges the myth that obesity is solely caused by calorie imbalance, emphasizing the role of gut-organ communication.
UT Health San Antonio Receives $12 Million to Advance Opioid Use Disorder Drug
UT Health San Antonio has been awarded $12 million to develop methocinnamox (MCAM) for opioid use disorder.
Semaglutide Investigated for Diabetes, Obesity in Spinal Cord Injury Patients
A clinical trial is underway to investigate the mechanisms behind diabetes and obesity in individuals with spinal cord injuries.